Transplanted organoids empower human preclinical assessment of drug candidate for the clinic.

The article presents the discussion on significant protection of kidney filter cells in human organoids and endogenous rat host kidneys. Topics include describing a scalable approach for human preclinical PD assessment of drugs targeting podocytes where cells being essential to the kidney filter barrier; and preclinical drug evaluation being induced pluripotent stem cell (iPSC)–derived organoids including kidney organoids.